News

Asianet Newsable on MSN36m
UroGen Pharma Stock Scores Bullish Price Target Revisions Up To $47 Following FDA Nod For Zusduri
UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.
AbbVie Moves From Blockbuster Loss To Market Domination
From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...
Why did Natco Pharma's share price slip 3% in trade today? Details here
Natco Pharma shares slipped in trade after the company said that the USFDA has issued one (1) observation in the Form-483 for ...